Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

NCT05182931 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

NCT NCT05182931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05182931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
July 14, 2022
Completion date
December 30, 2025
Enrollment
80 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer